Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With

Status Recruiting

Clinical Trial Summary

In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy. Prospective trials, including the previous Danish Watchful Waiting trials (NCT00952926, NCT02438839) in early rectal cancer have demonstrated high levels of organ preservation with dose-escalation, but it is unclear whether this was primarily due to tumor stage or dose level. The aim of the present study is to investigate if a higher dose of radiotherapy is superior compared to a standard dose in patients with early rectal cancer undergoing chemoradiotherapy with curative intent.

Clinical Trial Description

The main curative treatment modality for rectal cancer is surgery, potentially combined with chemotherapy and radiotherapy to lower the risk of local recurrence. In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of patients may avoid surgery altogether if they can achieve a complete response to chemoradiotherapy. These studies have mainly focused on locally advanced tumors with a high risk of local recurrence. Smaller, less advanced tumors appear to respond better to chemoradiotherapy, but the optimal treatment for non-surgical management has not been established. Prospective trials, including the previous Danish Watchful Waiting trials (NCT00952926, NCT02438839) in early rectal cancer have demonstrated high levels of organ preservation with dose-escalation, but it is unclear whether this was primarily due to tumor stage or dose level. High-level evidence is currently absent for the question of radiotherapy dose, especially in early stage cancers. The aim of the present study is to investigate if a higher dose of radiotherapy is superior compared to a standard dose in patients with early rectal cancer undergoing chemoradiotherapy with curative intent. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04095299
Study type	Interventional
Source	Vejle Hospital
Contact	Lars H Jensen, MD, PhD
Phone	+45 7940 6802
Email	lars.henrik.jensen@rsyd.dk
Status	Recruiting
Phase	Phase 2
Start date	January 20, 2020
Completion date	December 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04160650` - Educational Nursing Intervention Among Patients With Colorectal Cancer During Chemotherapy	N/A
Recruiting	`NCT02948348` - Study to Nivolumab Following Preoperative Chemoradiotherapy	Phase 1/Phase 2
Recruiting	`NCT01403883` - Psychological and Enterostomal Therapy Care	N/A
Recruiting	`NCT05179824` - Tempus Priority Study: A Pan-tumor Observational Study
Completed	`NCT04716010` - Developing and Evaluating Product Messaging	N/A
Completed	`NCT04319354` - Evaluation of cfDNA as a Marker of Response in Rectal Cancer	N/A
Completed	`NCT02641691` - Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum	Phase 2
Recruiting	`NCT03573791` - Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
Recruiting	`NCT04456283` - Survival of Patients With a Reduction in the Number of Lymph Nodes in Rectal Cancer After Neoadjuvant Chemoradiotherapy
Recruiting	`NCT05358704` - Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer	Phase 2
Not yet recruiting	`NCT03910283` - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer	N/A
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Recruiting	`NCT05887531` - Abdominopelvic Cancer Prehabilitation	N/A
Completed	`NCT04880772` - Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery	N/A
Completed	`NCT00271986` - Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection (LAR) for Recto-sigmoid Cancer	N/A
Active, not recruiting	`NCT06181201` - Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer
Not yet recruiting	`NCT03607643` - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	Phase 1/Phase 2
Terminated	`NCT04812743` - Colorectal Health Research Champions	N/A
Recruiting	`NCT03452774` - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting	`NCT05732389` - Immunotherapy in Patients With Early dMMR Rectal Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients — WW3

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms